Results of Generex Oral-Lyn Study Published

According to Generex Biotechnology, results of a study of Generex Oral-lyn, a treatment for Type 1 diabetes mellitus, have been published in Diabetes Technology & Therapeutics.

The study concluded that regular insulin and Generex Oral-lyn had similar glucodynamic effects in subjects with Type 1 diabetes mellitus receiving twice-daily insulin analogue as baseline therapy, Generex said.

Intensive monitoring and timely corrections with additional snacks, additional subcutaneous regular insulin or Generex Oral-lyn puffs resulted in appropriate glycemic control, as assessed by individual daily glycemic responses, the company said. Normal preprandial glycation decreased, but not significantly, the company added.